Ask HopeStage to review this study with me
Study ID: NCT00714688. We help you review the study, but cannot decide medical eligibility.
CompletedNCT00714688
Effectiveness of Effectiveness and Safety of Prolonged Release OROS Methylphenidate in ADHD
This study is completed in France, in the United Kingdom, in Switzerland, .... It is testing Effectiveness and Safety of Prolonged Release OROS Methylphenidate for ADHD.
ADHD, Attention Deficit/ Hyperactivity DisorderDrugFrom 18 Years to 65 Years
Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
Your next step
The official record suggests in-person participation through a lab. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include other factors that could make participation unsuitable and other treatments that could interfere with the study. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateFebruary 2008
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- France, United Kingdom, Switzerland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00714688
- Official title
- A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT00714688. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Belgium.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring behavioral or lifestyle intervention for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with adhd; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Cilag International NV, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT00700427
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, Finland, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
CompletedNCT04085172
TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
This study is completed in the United States, in the United Kingdom, in Belgium, .... It is testing TAK-503 for ADHD.
CompletedNCT05278104
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This study is completed in Germany. It focuses on ADHD.